Clinical trial NCT01542320: Effect of Probiotic Supplementation on Immune Function in Healthy Infants
Official title: Application of Therapeutic Microbiology to Improve Immunogenicity
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Inflammation
Keywords: probiotic
Lactobacillus reuteri DSM 17938
healthy infants
Lead sponsor: Emory University
Sponsor class: OTHER
Collaborators: name: The Gerber Foundation
First posted: 2012-03-02
Enrollment: 15
Sex: ALL
Minimum age (years): 6
Maximum age (years): 32
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: The purpose of this study is to understand how a probiotic might change the immune response of healthy infants.

Detailed description: PROBLEM OF INTEREST: Lactic acid bacteria known as probiotics have been given to children and adults to prevent and treat gastrointestinal infections and to maintain intestinal health. This pilot study will collect information (biomarkers) of inflammation and immune response from healthy infants.

HOW THE PROBLEM WILL BE STUDIED: The investigators will give an active Lactobacillus-containing probiotic or an inactive placebo without Lactobacillus to 38 healthy infants in the metropolitan Atlanta area from 2 weeks before until 2 weeks after they complete their rotavirus vaccine series. Half will be assigned to receive the active probiotic, half to receive the placebo. Neither the investigators nor the parent/ guardian of the study subject will know whether their infant is receiving the probiotic or placebo. A teaspoon of blood and a stool sample will be collected from each infant before they start taking the active probiotic or placebo and 2 weeks after they complete their rotavirus vaccine series. Each infant will receive the probiotic or placebo product for 2 weeks before starting their rotavirus vaccine series until 2 weeks after they complete their rotavirus vaccine series. The blood and stool samples will be examined for levels of inflammatory markers and measures of immune response. The stool samples may be stored for the later study of probiotic bacteria as well as for other bacteria and viruses. These results will help to determine if this Lactobacillus containing probiotic has an effect on immune response and inflammation in healthy infants.

HOW RESEARCH WILL ADVANCE SCIENTIFIC KNOWLEDGE AND HUMAN HEALTH: This study will provide new information about the impact of giving a Lactobacillus-containing probiotic supplement to healthy infants. CURRENT STANDARD OF CARE: The current standard of care is for infants to receive a probiotic at the discretion of their caregiver. By studying probiotic administration in a controlled way with a fixed dose schedule and a well categorized probiotic, and measuring blood and stool markers, the investigators hope to better understand the impact of a probiotic on immune response and inflammation.

Eligibility criteria: Inclusion Criteria:

* Healthy infant
* Eligible for rotavirus immunization series
* No recognized immunodeficiency
* Ability to comply with study procedures

Exclusion Criteria:

* Ineligible for rotavirus immunization series
* Recognized immunodeficiency
* Inability to comply with study procedures

Primary outcomes:
measure: Biomarkers of immune response
timeFrame: Between 18 and 32 weeks of age
Secondary outcomes:
Other outcomes:
Locations:
city: Atlanta
country: United States
facility: Emory Children's Center
state: Georgia
Study officials:
affiliation: Emory University
name: Andi L Shane, MD, MPH, MSc
role: PRINCIPAL_INVESTIGATOR
References: